Emily E. Morin
Impact in
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
-
- Cancer, Lipids, and Metabolism
Papers in
- Surgery 10
- Cholesterol and Lipid Metabolism 7
- Lipoproteins and Cardiovascular Health 5
-
- Cancer, Lipids, and Metabolism 4
- Co-authors
- Anna Schwendeman (15 shared papers)Hongliang He (2 shared papers)Lisha Liu (1 shared paper)Min Liu (1 shared paper)Minzhi Yu (6 shared papers)Ling Guo (2 shared papers)Wenmin Yuan (6 shared papers)Ekaterina I. Shishatskaya (1 shared paper)
- Journals
- Frontiers in Pharmacology (2 papers)Journal of Lipid Research (2 papers)Nanomedicine Nanotechnology Biology and Medicine (1 paper)Endocrinology (1 paper)Journal of Controlled Release (1 paper)
- Partner nations
- United StatesChinaRussia
In The Last Decade
Emily E. Morin
20 papers receiving 1.1k citations
Emily E. Morin's Hit Papers
Peers
Comparison fields: 5 of 92
- Biomaterials 320
- Cancer Research 129
- Endocrinology, Diabetes and Metabolism 141
- Immunology 166
- Pharmaceutical Science 44
Countries citing papers authored by Emily E. Morin
This map shows the geographic impact of Emily E. Morin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily E. Morin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily E. Morin more than expected).
Fields of papers citing papers by Emily E. Morin
This network shows the impact of papers produced by Emily E. Morin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily E. Morin. The network helps show where Emily E. Morin may publish in the future.
Co-authors
The 25 scholars most cited alongside Emily E. Morin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures Hit paper breakdown → | 2019 | 468 |
| 2 | 2018 | 126 | |
| 3 | 2015 | 97 | |
| 4 | 2017 | 86 | |
| 5 | 2015 | 80 | |
| 6 | 2019 | 61 | |
| 7 | 2020 | 38 | |
| 8 | 2022 | 30 | |
| 9 | 2018 | 27 | |
| 10 | 2016 | 27 | |
| 11 | 2017 | 20 | |
| 12 | 2019 | 18 | |
| 13 | 2020 | 12 | |
| 14 | 2022 | 11 | |
| 15 | 2016 | 6 | |
| 16 | 2022 | 5 | |
| 17 | 2023 | 3 | |
| 18 | 2022 | 3 | |
| 19 | 2023 | 3 | |
| 20 | 2022 | 1 |
About Emily E. Morin
Emily E. Morin is a scholar working on Surgery, Cancer Research, Molecular Biology, Immunology and Cardiology and Cardiovascular Medicine, having authored 21 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cholesterol and Lipid Metabolism (7 papers), Lipoproteins and Cardiovascular Health (5 papers), Cancer, Lipids, and Metabolism (4 papers), Drug Transport and Resistance Mechanisms (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers), Sepsis Diagnosis and Treatment (2 papers), Systemic Lupus Erythematosus Research (2 papers) and Peroxisome Proliferator-Activated Receptors (2 papers). The work is most often cited by research in Biomaterials (320 citations), Cancer Research (129 citations), Endocrinology, Diabetes and Metabolism (141 citations), Immunology (166 citations) and Pharmaceutical Science (44 citations). Emily E. Morin has collaborated with scholars based in United States, China and Russia. Frequent co-authors include Anna Schwendeman, Hongliang He, Lisha Liu, Min Liu, Minzhi Yu, Ling Guo, Wenmin Yuan, Ekaterina I. Shishatskaya, Steven P. Schwendeman and Yanhong Guo. Their work appears in journals such as Frontiers in Pharmacology, Journal of Lipid Research, Nanomedicine Nanotechnology Biology and Medicine, Endocrinology and Journal of Controlled Release.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.